Breast Cancer Susceptibility Panel Testing Rarely Found Actionable Mutations


June 17, 2014

In continuing coverage, HemOnc Today reports on an abstract presented at the American Society of Clinical Oncology annual meeting on large-panel genetic testing in breast cancer—which tend to produce more questions than they answer. In a study of 278 women with early-onset breast cancer who did not have the BRCA genes, the researchers found that only 2.5 percent of the patients had inherited mutations that were actually clinically actionable. “We’re in a time where the testing technology has outpaced what we know from a clinical standpoint,” said Kara Maxwell, MD, PhD, a fellow in the division of Hematology-Oncology in the Abramson Cancer Center. Senior authors on the abstract include Susan Domchek, MD, director of the Basser Research Center for BRCA, and Katherine Nathanson, MD, an associate professor in the division of Translational Medicine and Chief Oncogenomics Physician.

HemOnc Today article